Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

May 27, 2023

Study Completion Date

May 27, 2023

Conditions

GonorrheaInfection, Bacterial

Interventions

DRUG

Gepotidacin

Single oral dose of 1500 mg gepotidacin

Trial Locations (4)

MUVienna, Vienna

CHRU TOURS Département Urologie, Tours

CHU POITIERS Département ORL, Poitiers

CHU POITIERS Département Urologie, Poitiers

All Listed Sponsors

collaborator

Medical University of Vienna

OTHER

lead

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

NCT04484740 - Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue | Biotech Hunter | Biotech Hunter